BioWorld

Dec. 30, 2004

FDA Gives Approval For Prialt; Elan Prepares January Launch

Elan Corp. plc will be ringing in the new year with another product approval, this time for the snail venom pain product, Prialt. (BioWorld Today) Read More

Genzyme's Clofarabine Gets FDA Nod For Pediatric Use

Cell Division Enzymes Offer Host Of Targets For New Cancer Drugs

Holiday notice

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...